Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HL-040XC | Experimental | Once daily, administered orally, 8 week |
|
| Atorvastatin | Active Comparator | Once daily, administered orally, 8 week |
|
| Losartan | Active Comparator | Once daily, administered orally, 8 week |
|
| Placebo | Placebo Comparator | Once daily, administered orally, 8 week |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin | Drug | Once daily, administered orally, 8 week |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline to 8 week in SiDBP (Sitting Diastolic Blood Pressure) | Baseline and 8 week | |
| Percent change from baseline to 8 week in LDL-Cholesterol | Baseline and 8 week |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients reaching treatment goals according to NCEP ATP III Guideline and Blood Pressure Responder according to JNC VII Guideline. | Baseline and 4, 8 week |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chang-Gyu Park, Medicine | Department of Cardiovascular, Korea University Guro Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Korea University Guro Hospital | Seoul | Seoul | South Korea |
Not provided
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| D006949 | Hyperlipidemias |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D050171 | Dyslipidemias |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| D019808 | Losartan |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Losartan | Drug | Once daily, administered orally, 8 week |
|
|
| Placebo | Drug | Once daily, administered orally, 8 week |
|
| HL-040XC | Drug | Once daily, administered orally, 8 week |
|
| D052439 |
| Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006538 |
| Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D007093 | Imidazoles |
| D013777 | Tetrazoles |